Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV
- PMID: 36240815
- PMCID: PMC9577481
- DOI: 10.1016/S2214-109X(22)00408-9
Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV
Conflict of interest statement
WDFV reports grants from USAID, Unitaid, the South African Medical Research Council, National Institutes of Health, Bill & Melinda Gates Foundation, and ViiV Healthcare; personal fees and non-financial support from ViiV and Gilead Sciences; and personal fees from Mylan, Merk, Adcock-Ingram, Aspen, Abbott, Roche, Johnson and Johnson, Sanofi, and Virology Education. LV declares no competing interests.
Comment on
-
Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania.Lancet Glob Health. 2022 Nov;10(11):e1646-e1654. doi: 10.1016/S2214-109X(22)00372-2. Lancet Glob Health. 2022. PMID: 36240830 Free PMC article.
References
-
- UNAIDS Global HIV & AIDS statistics – Fact sheet. Geneva, Switzerland. 2021. https://www.unaids.org/en/resources/fact-sheet
-
- WHO . World Health Organization; Geneva: 2021. Global tuberculosis report 2021.https://apps.who.int/iris/handle/10665/346387
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
